Drug network identification predicts injecting risk behavior among people who inject drugs on hepatitis C virus treatment in Tayside, Scotland

References

• Blach S, Terrault N, Tacke F, et al. Global change in hepatitis C virus prevalence and cascade of care between 2015 and 2020: a modelling study. Lancet Gastroenterol Hepatol. 2022;7(5):396–415. doi:10.1016/S2468-1253(21)00472-6
   PubMed Web of Science ®Google Scholar
• World Health Organization. 2016. Global Health Sector Strategy on Viral Hepatitis 2016–2021: Towards ending viral hepatitis. Geneva: WHO Document Production Services. Accessed February 22, 2022. https://apps.who.int/iris/handle/10665/246177.
   Google Scholar
• World Health Organization. 2021. Global progress report on HIV, viral hepatitis and sexually transmitted infections, 2021. Geneva: World Health Organization. Accessed February 22, 2022. https://www.who.int/publications/i/item/9789240027077.
   Google Scholar
• Grebely J, Larney S, Peacock A, et al. Global, regional, and country-level estimates of hepatitis C infection among people who have recently injected drugs. Addiction. 2019;114(1):150–166. doi:10.1111/add.14393
   PubMed Web of Science ®Google Scholar
• Hajarizadeh B, Cunningham EB, Reid H, Law M, Dore GJ, Grebely J. Direct-acting antiviral treatment for hepatitis C among people who use or inject drugs: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol. 2018;3(11):754–767. doi:10.1016/S2468-1253(18)30304-2
   PubMed Web of Science ®Google Scholar
• Lazarus J, Pericàs J, Picchio C, et al. We know DAAs work, so now what? Simplifying models of care to enhance the hepatitis C cascade. J Intern Med. 2019;286(5):503–525. doi:10.1111/joim.12972
   PubMed Web of Science ®Google Scholar
• Oru E, Trickey A, Shirali R, Kanters S, Easterbrook P. Decentralisation, integration, and task-shifting in hepatitis C virus infection testing and treatment: a global systematic review and meta-analysis. Lancet Glob Health. 2021;9(4):e431–e445. doi:10.1016/S2214-109X(20)30505-2
   PubMed Web of Science ®Google Scholar
• Falade-Nwulia O, Sulkowski M, Merkow A, Latkin C, Mehta S. Understanding and addressing hepatitis C reinfection in the oral direct-acting antiviral era. J Viral Hepat. 2018;25(3):220–227. doi:10.1111/jvh.12859
   PubMed Web of Science ®Google Scholar
• Hellard M, Rolls D, Sacks Davis R ‐, et al. The impact of injecting networks on hepatitis C transmission and treatment in people who inject drugs. Hepatology. 2014;60(6):1861–1870. doi:10.1002/hep.27403
   PubMed Web of Science ®Google Scholar
• Hellard M, McBryde E, Sacks Davis R, et al. Hepatitis C transmission and treatment as prevention—The role of the injecting network. Int J Drug Policy. 2015;26(10):958–962. doi:10.1016/j.drugpo.2015.05.006
   PubMed Web of Science ®Google Scholar
• Lafferty L, Rance J, Treloar C. Who goes first? Understanding hepatitis C risk among injecting networks in the prison setting. Drug Alcohol Depend. 2018;183:96–101. doi:10.1016/j.drugalcdep.2017.10.030
   PubMed Web of Science ®Google Scholar
• Yeung A, Palmateer N, Dillon J, et al. Population-level estimates of hepatitis C reinfection post scale-up of direct-acting antivirals among people who inject drugs. J Hepatol. 2022;76(3):549–557. doi:10.1016/j.jhep.2021.09.038
   PubMed Web of Science ®Google Scholar
• Byrne C, Beer L, Inglis S, et al. Real‐world outcomes of rapid regional hepatitis C virus treatment scale‐up among people who inject drugs in Tayside, Scotland. Aliment Pharmacol Ther. 2022;55(5):568–579. doi:10.1111/apt.16728
   PubMed Web of Science ®Google Scholar
• Public Health Scotland. Injecting Equipment Provision in Scotland: 2017/18, 2018/19 and 2019/20. Public Health Scotland; 2020. Table 3.2. Accessed February 23, 2022. https://publichealthscotland.scot/publications/injecting-equipment-provision-in-scotland/injecting-equipment-provision-in-scotland-2020-to-2021/.
   Google Scholar
• Olafsson S, Fridriksdottir R, Love T, et al. Cascade of care during the first 36 months of the treatment as prevention for hepatitis C (TraP HepC) programme in Iceland: a population-based study. Lancet Gastroenterol Hepatol. 2021;6(8):628–637. doi:10.1016/S2468-1253(21)00137-0
   PubMed Web of Science ®Google Scholar
• Bryant J, Brener L, Pepolim L, Harrod M. Care, agency and criminality: Making sense of authorised extended distribution in the accounts of key stakeholders. Int J Drug Policy. 2019;71:56–61. doi:10.1016/j.drugpo.2019.06.008
   PubMed Web of Science ®Google Scholar
• Kolla G, Strike C. ‘It’s too much, I’m getting really tired of it’: Overdose response and structural vulnerabilities among harm reduction workers in community settings. Int J Drug Policy. 2019;74:127–135. doi:10.1016/j.drugpo.2019.09.012
   PubMed Web of Science ®Google Scholar
• Small W, Wood E, Tobin D, Rikley J, Lapushinsky D, Kerr T. The injection support team: a peer-driven program to address unsafe injecting in a Canadian setting. Subst Use Misuse. 2012;47(5):491–501. doi:10.3109/10826084.2012.644107
   PubMed Web of Science ®Google Scholar
• Larney S, Peacock A, Leung J, et al. Global, regional, and country-level coverage of interventions to prevent and manage HIV and hepatitis C among people who inject drugs: a systematic review. Lancet Glob Health. 2017;5(12):e1208–e1220. doi:10.1016/S2214-109X(17)30373-X
   PubMed Web of Science ®Google Scholar
• Reynolds B. A review of delay-discounting research with humans: relations to drug use and gambling. Behav Pharmacol. 2006;17(8):651–667. doi:10.1097/FBP.0b013e3280115f99
   PubMed Web of Science ®Google Scholar
• Robles E, Huang B, Simpson P, McMillan D. Delay discounting, impulsiveness, and addiction severity in opioid-dependent patients. J Subst Abuse Treat. 2011;41(4):354–362. doi:10.1016/j.jsat.2011.05.003
   PubMed Web of Science ®Google Scholar
• Ashe M, Newman M, Wilson S. Delay discounting and the use of mindful attention versus distraction in the treatment of drug addiction: A conceptual review. J Exp Anal Behav. 2015;103(1):234–248. doi:10.1002/jeab.122
   PubMed Web of Science ®Google Scholar
• Bailey S, Ouellet L, Mackesy-Amiti M, et al. Perceived risk, peer influences, and injection partner type predict receptive syringe sharing among young adult injection drug users in five U.S. cities. Drug Alcohol Depend. 2007;91:S18–S29. doi:10.1016/j.drugalcdep.2007.02.014
   PubMed Web of Science ®Google Scholar
• Bloor M, Robertson M, McKeganey N, Neale J. Theorising equipment-sharing in a cohort of Scottish drug users. Health Risk Soc. 2008;10(6):599–607. doi:10.1080/13698570802533697
   Web of Science ®Google Scholar
• Broz D, Ouellet L. Prevalence and correlates of former injection drug use among young noninjecting heroin users in Chicago. Subst Use Misuse. 2010;45(12):2000–2025. doi:10.3109/10826081003682875
   PubMed Web of Science ®Google Scholar
• Cepeda A, Kaplan C, Neaigus A, Cano M, Villarreal Y, Valdez A. Injecting transition risk and depression among Mexican American non-injecting heroin users. Drug Alcohol Depend. 2012;125:S12–S17. doi:10.1016/j.drugalcdep.2012.05.035
   PubMed Web of Science ®Google Scholar
• Heimer R, Barbour R, Palacios W, Nichols L, Grau L. Associations between injection risk and community disadvantage among suburban injection drug users in Southwestern Connecticut, USA. AIDS Behav. 2014;18(3):452–463. doi:10.1007/s10461-013-0572-3
   PubMed Web of Science ®Google Scholar
• McGowan C, Harris M, Rhodes T. Hepatitis C avoidance in injection drug users: a typology of possible protective practices. PLoS One. 2013;8(10):e77038. doi:10.1371/journal.pone.0077038
   PubMed Web of Science ®Google Scholar
• Neaigus A, Gyarmathy V, Miller M, Frajzyngier V, Friedman S, Des Jarlais D. Transitions to injecting drug use among noninjecting heroin users. J Acquir Immune Defic Syndr. 2006;41(4):493–503. doi:10.1097/01.qai.0000186391.49205.3b
   PubMed Web of Science ®Google Scholar
• Roux P, Lions C, Michel L, ANRS Methaville Study Group, et al. Factors associated with HCV risk practices in methadone-maintained patients: the importance of considering the couple in prevention interventions. Subst Abuse Treat Prev Policy. 2014;9(1):37. doi:10.1186/1747-597X-9-37
   PubMedGoogle Scholar
• Sani F, Madhok V, Norbury M, Dugard P, Wakefield J. Greater number of group identifications is associated with healthier behaviour: Evidence from a Scottish community sample. Br J Health Psychol. 2015;20(3):466–481. doi:10.1111/bjhp.12119
   PubMed Web of Science ®Google Scholar
• Haslam C, Jetten J, Cruwys T, Dingle G, Haslam A. The New Psychology of Health: Unlocking the Social Cure. 1st ed. Abingdon: Routledge; 2018.
   Google Scholar
• Cruwys T, Haslam SA, Dingle GA, Haslam C, Jetten J. Depression and social identity. Pers Soc Psychol Rev. 2014;18(3):215–238. doi:10.1177/1088868314523839
   PubMed Web of Science ®Google Scholar
• Brener L, Broady T, Cama E, Hopwood M, Byrne J, Treloar C. Positive effects of community attachment on internalised stigma and wellbeing among people who inject drugs. Int J Drug Policy. 2021;97:103323. doi:10.1016/j.drugpo.2021.103323
   PubMed Web of Science ®Google Scholar
• Gossop M, Marsden J, Stewart D, Treacy S. Reduced injection risk and sexual risk behaviours after drug misuse treatment: results from the National Treatment Outcome Research Study. AIDS Care. 2002;14(1):77–93. doi:10.1080/09540120220097955
   PubMed Web of Science ®Google Scholar
• Fairbairn N, Small W, van Borek N, Wood E, Kerr T. Social structural factors that shape assisted injecting practices among injection drug users in Vancouver, Canada: a qualitative study. Harm Reduct J. 2010;7:20–27. doi:10.1186/1477-7517-7-20
   PubMed Web of Science ®Google Scholar
• Wagner K, Lankenau S, Palinkas L, Richardson J, Chou C, Unger J. The perceived consequences of safer injection: an exploration of qualitative findings and gender differences. Psychol Health Med. 2010;15(5):560–573. doi:10.1080/13548506.2010.498890
   PubMed Web of Science ®Google Scholar
• Langston S, Edwards M, Lyvers M, Stapletone P. Illness perceptions and treatment outcomes in Hepatitis C. New Zealand J Psychol. 2016;45(2):22–28.
   Google Scholar
• Langston S, Edwards M, Lyvers M, Stapleton P. The self-regulatory model of illness and adjustment outcomes in hepatitis C. Profession Psychol Res Pract. 2017;48(5):317–326. doi:10.1037/pro0000136
   Web of Science ®Google Scholar
• Langston S, Edwards M, Lyvers M. Illness perceptions, coping, benefit finding, and adjustment in individuals with Hepatitis C. Aust Psychol. 2018;53(1):87–96. doi:10.1111/ap.12255
   Web of Science ®Google Scholar
• Zalai D, Sherman M, McShane K, Shapiro C, Carney C. The importance of fatigue cognitions in chronic hepatitis C infection. J Psychosom Res. 2015;78(2):193–198. doi:10.1016/j.jpsychores.2014.11.011
   PubMed Web of Science ®Google Scholar
• Leventhal H, Meyer D, Nerenz D. Illness representations and coping with health threats. In Baum A, Taylor S, Singer J, edHandbook of Psychology and Health: Social Psychological Aspects of Health. 4th ed. New Jersey: Erlbaum; 1980. p. 219–252.
   Google Scholar
• Stimson G, Jones S, Sullivan D, Chalmers C. A short questionnaire (IRQ) to assess injecting risk behaviour. Addiction. 1998;93(3):337–347. doi:10.1046/j.1360-0443.1998.9333373.x
   PubMed Web of Science ®Google Scholar
• Sani F, Madhok V, Norbury M, Dugard P, Wakefield J. Greater number of group identifications is associated with lower odds of being depressed: evidence from a Scottish community sample. Soc Psychiatry Psychiatr Epidemiol. 2015;50(9):1389–1397. doi:10.1007/s00127-015-1076-4
   PubMed Web of Science ®Google Scholar
• Spitzer RL, Kroenke K, Williams JB. Validation and utility of a self-report version of PRIME-MD: The PHQ Primary Care Study. JAMA. 1999;282(18):1737–1744. doi:10.1001/jama.282.18.1737
   PubMed Web of Science ®Google Scholar
• Spitzer R, Kroenke K, Williams J, Löwe B. A brief measure for assessing generalized anxiety disorder. Arch Intern Med. 2006;166(10):1092–1097. doi:10.1001/archinte.166.10.1092
   PubMed Web of Science ®Google Scholar
• Prins A, Bovin MJ, Smolenski DJ, et al. The Primary Care PTSD screen for DSM-5 (PC-PTSD-5): development and evaluation within a veteran primary care sample. J Gen Intern Med. 2016;31(10):1206–1211. doi:10.1007/s11606-016-3703-5
   PubMed Web of Science ®Google Scholar
• Broadbent E, Petrie K, Main J, Weinman J. The Brief Illness Perception Questionnaire. J Psychosom Res. 2006;60(6):631–637. doi:10.1016/j.jpsychores.2005.10.020
   PubMed Web of Science ®Google Scholar
• Hologic. Aptima HCV Quant Dx Assay; 2018. https://www.hologic.com/sites/default/files/2019-03/AW-14498_002_01_0.pdf. Accessed November 3, 2021.
   Google Scholar
• Chevaliez S, Bouvier-Alias M, Pawlotsky J. Performance of the abbott real-time PCR assay using m 2000sp and m 2000rt for Hepatitis C Virus RNA quantification. J Clin Microbiol. 2009;47(6):1726–1732. doi:10.1128/JCM.01300-08
   PubMed Web of Science ®Google Scholar
• Field A. Discovering Statistics Using IBM SPSS Statistics. 5th ed. London: Sage; 2018.
   Google Scholar
• Gaskin S, Brazil C, Pickering D. The sharing of injecting paraphernalia by intravenous drug users (IDUs) within a Worcestershire cohort, with specific reference to water and filters. Int J Drug Policy. 2000;11(6):423–435. doi:10.1016/S0955-3959(00)00069-4
   PubMedGoogle Scholar
• Gossop M, Griffiths P, Powis B, Williamson S, Fountain J, Strang J. Continuing drug risk behaviour: Shared use of injecting paraphernalia among London heroin injectors. AIDS Care. 1997;9(6):651–660. doi:10.1080/09540129750124687
   PubMed Web of Science ®Google Scholar
• Unger J, Kipke M, De Rosa C, Hyde J, Ritt-Olson A, Montgomery S. Needle-sharing among young IV drug users and their social network members: The influence of the injection partner’s characteristics on HIV risk behavior. Addict Behav. 2006;31(9):1607–1618. doi:10.1016/j.addbeh.2005.12.007
   PubMed Web of Science ®Google Scholar
• Day C, Ross J, Dietze P, Dolan K. Initiation to heroin injecting among heroin users in Sydney, Australia: Cross-sectional survey. Harm Reduct J. 2005;2(1):2. doi:10.1186/1477-7517-2-2
   PubMedGoogle Scholar
• Fraser S, Rance J, Treloar C. Hepatitis C prevention and convenience: why do people who inject drugs in sexual partnerships ‘run out’ of sterile equipment? Crit Public Health. 2016;26(3):294–306. doi:10.1080/09581596.2015.1036839
   Web of Science ®Google Scholar
• Latkin C, Yang C, Srikrishnan AK, et al. The relationship between social network factors, HIV, and Hepatitis C among injection drug users in Chennai, India. Drug Alcohol Depend. 2011;117(1):50–54. doi:10.1016/j.drugalcdep.2011.01.005
   PubMed Web of Science ®Google Scholar
• Nasir S, Rosenthal D. The social context of initiation into injecting drugs in the slums of Makassar, Indonesia. Int J Drug Policy. 2009;20(3):237–243. doi:10.1016/j.drugpo.2008.02.001
   PubMed Web of Science ®Google Scholar
• De P, Cox J, Boivin J, Platt R, Jolly A. Social network-related risk factors for bloodborne virus infections among injection drug users receiving syringes through secondary exchange. J Urban Health. 2008;85(1):77–89. doi:10.1007/s11524-007-9225-z
   PubMed Web of Science ®Google Scholar
• Dunn M, Degenhardt L, Bruno R. Transition to and from injecting drug use among regular ecstasy users. Addict Behav. 2010;35(10):909–912. doi:10.1016/j.addbeh.2010.06.007
   PubMed Web of Science ®Google Scholar
• Shaw S, Shah L, Jolly A, Wylie J. Determinants of injection drug user (IDU) syringe sharing: the relationship between availability of syringes and risk network member characteristics in Winnipeg, Canada. Addiction. 2007;102(10):1626–1635. doi:10.1111/j.1360-0443.2007.01940.x
   PubMed Web of Science ®Google Scholar
• Marshall Z, Dechman M, Minichiello A, Alcock L, Harris G. Peering into the literature: A systematic review of the roles of people who inject drugs in harm reduction initiatives. Drug Alcohol Depend. 2015;151:1–14. doi:10.1016/j.drugalcdep.2015.03.002
   PubMed Web of Science ®Google Scholar
• Silano J, Treloar C, Leadbeatter K, Davidson S, Doidge J. Peer-facilitated treatment access for hepatitis C: the Live Hep C Free project. Harm Reduct J. 2022;19(1). doi:10.1186/s12954-022-00619-3
   PubMed Web of Science ®Google Scholar
• INHSU, 2021. A peer-led approach to hepatitis C testing and treatment. [online] Available at: https://www.inhsu.org/infographic/a-peer-led-approach-to-hepatitis-c/. Accessed August 31, 2022.
   Google Scholar
• Savolainen I, Kaakinen M, Sirola A, Oksanen A. Addictive behaviors and psychological distress among adolescents and emerging adults: A mediating role of peer group identification. Addict Behav Rep. 2018;7:75–81. doi:10.1016/j.abrep.2018.03.002
   PubMedGoogle Scholar
• Sussman S, Dent C, McCullar W. Group self-identification as a prospective predictor of drug use and violence in high-risk youth. Psychol Addict Behav. 2000;14(2):192–196. doi:10.1037/0893-164X.14.2.192
   PubMed Web of Science ®Google Scholar
• Malaguti A, Sani F, Stephens B, Ahmad F, Dugard P, Dillon J, ERADICATE-C Study Group. Change in injecting behaviour among people treated for hepatitis C virus: The role of intimate partnerships. J Viral Hepat. 2019;26(1):65–72. doi:10.1111/jvh.13009
   PubMed Web of Science ®Google Scholar
• Rance J, Treloar C, Fraser S, Bryant J, Rhodes T. “Don’t think I’m going to leave you over it”: Accounts of changing hepatitis C status among couples who inject drugs. Drug Alcohol Depend. 2017;173:78–84. doi:10.1016/j.drugalcdep.2016.12.020
   PubMed Web of Science ®Google Scholar
• Mohamed I, Ahmad H, Hassaan S, Hassan S. Assessment of anxiety and depression among substance use disorder patients: a case-control study. Middle East Curr Psychiatry. 2020;27(1). doi:10.1186/s43045-020-00029-w
   Google Scholar
• von Hippel C, Brener L, Horwitz R. Implicit and explicit internalized stigma: Relationship with risky behaviors, psychosocial functioning and healthcare access among people who inject drugs. Addict Behav. 2018;76:305–311. doi:10.1016/j.addbeh.2017.08.036
   PubMed Web of Science ®Google Scholar
• Mackesy-Amiti M, Donenberg G, Ouellet L. Psychiatric correlates of injection risk behavior among young people who inject drugs. Psychol Addict Behav. 2014;28(4):1089–1095. doi:10.1037/a0036390
   PubMed Web of Science ®Google Scholar
• Sedgwick P. Cross sectional studies: advantages and disadvantages. BMJ. 2014;348(mar26 2):g2276–g2276. doi:10.1136/bmj.g2276
   Google Scholar